Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate

doi:10.12998/wjcc.v10.i6.1764

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 6

This Article

Peer-Review Report of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6864)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

431

WORD

114

HTML

3222

Tables (1-2)

641

Sum=4408

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

612

Download

1854

Sum=2466

Feb 26, 2022 (publication date) through Feb 27, 2026

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Clin Cases. Feb 26, 2022; 10(6): 1764-1774
Published online Feb 26, 2022. doi: 10.12998/wjcc.v10.i6.1764

Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate

Ahmed Kamal, Ahmed Elsheaita, Mahmoud Abdelnabi

Ahmed Kamal, Internal Medicine Department, Faculty of Medicine Alexandria University, Alexandria 21131, Egypt

Ahmed Elsheaita, Mahmoud Abdelnabi, Clinical and Experimental Internal Medicine Department, Medical Research Institute Alexandria University, Alexandria 21561, Egypt

Mahmoud Abdelnabi, Internal Medicine Department, Texas Tech University Health Science Center, Lubbock, TX 79430, United States

Author contributions: All authors contributed equally to the literature review, data collection, and manuscript writing, and approved the final version of the manuscript.

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

Corresponding author: Mahmoud Abdelnabi, MD, MSc, Internal Medicine Department, Texas Tech University Health Science Center, 3601 4th St, Lubbock, TX 79430, United States. mahmoud.hassan.abdelnabi@outlook.com

Received: May 16, 2021
Peer-review started: May 16, 2021
First decision: July 27, 2021
Revised: August 5, 2021
Accepted: January 27, 2022
Article in press: January 27, 2022
Published online: February 26, 2022
Processing time: 282 Days and 21.7 Hours

Core Tip

Core Tip: Present evidence does not confirm or repudiate a higher rate of de novo hepatocellular carcinoma (HCC) occurrence or recurrence related to direct-acting antiviral agent (DAA) therapy. More trials are required to determine whether there is an association between HCC occurrence or recurrence and DAA or if it is mainly related to preexisting liver cirrhosis.